688443 Chongqing Genrix Biopharmaceutical
- 31.00
- -0.92-2.88%
Chongqing Genrix Biopharmaceutical News
Zhixiang Jintai: Repurchase Report on the Repurchase of Shares Using Centralized Bidding Transactions
Zhixiang Jintai: Announcement on the progress of share repurchases
Zhixiang Jintai: Announcement on the shareholding status of the top ten shareholders and the top ten shareholders with unlimited sales conditions for share repurchases
Announcement on the shareholding situation of the top ten shareholders and the top ten shareholders with unlimited sale conditions for share repurchases
Zhixiang Jintai: A Plan to Repurchase Shares Through Centralized Bidding
Voluntary disclosure announcement on approval for marketing of celizumab as an indication for moderate to severe plaque psoriasis
Voluntary disclosure regarding the commencement of Phase III clinical trials for GR2001 injection.
Voluntary disclosure announcement on the inclusion of GR1803 injection solution in the list of breakthrough therapeutic varieties.
Voluntary disclosure regarding the launch of Phase III clinical trial for GR1802 injection for the treatment of chronic sinusitis with nasal polyps.
Action plan for "Improving Quality, Increasing Efficiency, and Returning to Benefits" for the year 2024.
Announcement on the voluntary disclosure of GR2001 injection being included in the list of breakthrough therapeutic varieties.
Legal Opinion from Shanghai Jintiancheng Law Firm Regarding the 2023 Shareholders' Meeting of Chongqing Zhixiang Jintai Biopharmaceutical Co., Ltd.
Announcement of Resolutions of the Shareholders' Meeting for the Fiscal Year 2023
Announcement of reply to regulatory inquiry letter regarding information disclosure of 2023 annual report.
Materials for the 2023 Annual Shareholders Meeting.
Report on the performance of supervisory duties by the Board of Auditors on accounting firms
Notice on convening the 2023 Annual General Meeting of Shareholders
Announcement on the appointment of senior management
Special Report on 2023 Non-operating Capital Occupation and Other Related Capital Transactions
2023 Internal Control Evaluation Report
Analysis
Price Target
No Data
No Data